Published by
Ministry of Health, Labour and Welfare

Translated by
Pharmaceuticals and Medical Devices Agency

This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of Precautions

Topiroxostat

July 9, 2019

Therapeutic category

Gout preparations

Non-proprietary name

Topiroxostat

Safety measure

Precautions should be revised in the package insert.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp

Revision in line with the Instructions for Package Inserts of Prescription Drugs, PAB Notification No. 606 by the Director General of Pharmaceutical Affairs Bureau, MHW, dated April 25, 1997 (Old instructions): Revised language is underlined.

Current	Revision
Other Precautions (N/A)	Other Precautions A double-blind, non-inferiority study with febuxostat and allopurinol was conducted overseas in patients with gout who had cardiovascular disease. Results showed that febuxostat was non-inferior to allopurinol for the primary endpoint (a composite endpoint composed of cardiovascular death, nonfatal myocardial infarction, nonfatal cerebral stroke, and urgent revascularization for unstable angina). However, of the secondary endpoints, the incidence of cardiovascular death was 4.3% (134/3098 patients) in the febuxostat group, higher than 3.2% (100/3092 patients) in the allopurinol group (hazard ratio [95%CI]: 1.34 [1.03, 1.73]). Among cardiovascular deaths, sudden cardiac death was most commonly observed in both groups (febuxostat group: 2.7% (83/3098 patients), allopurinol group 1.8% (56/3092 patients).) The incidence of all-cause death in the febuxostat group and in the allopurinol group was 7.8% (243/3098 patients) and 6.4% (199/3092 patients), respectively, higher in the febuxostat group (HR was 1.22 [95%CI: 1.01-1.47].)

N/A: Not Applicable, because the section is not included in the current package insert.